Putnam

Orphan drugs for rare diseases are becoming increasingly pivotal in the global pharmaceutical landscape, now representing 16% of pharma revenue. As the rare disease market consistently grows each year, it is expected to reach around $336B globally by 2030. In our latest white paper, dive into our analysis to understand the challenges and opportunities in rare disease drug development, and discover strategies to navigate this dynamic landscape. Download your copy here: https://lnkd.in/eRj3qrUD #RareDisease #Pharma #Biotech #HealthcareInnovation #WhitePaper

Not sure where to begin with all of your structured and unstructured data? With ClarityNav, our experts can help you sort through this data efficiently, determining key insights to drive your strategy. Hear from Lori Klein, PharmD, Partner, Medical & Scientific Affairs practice lead and learn more: https://lnkd.in/e7CcPcJR #AI #GenAI #Data #Insights #Healthcare #MedicalAffairs #ClarityNav

The rare disease market has seen remarkable growth over the past decade, driven by regulatory incentives for orphan drugs and the commercial potential of high unmet-need diseases. However, despite significant pharma and biotech interest, numerous diseases still lack effective therapies. In our latest white paper, dive into our comprehensive analysis to understand the challenges and opportunities in rare disease drug development, and discover strategies to navigate this dynamic landscape. Download your copy here: https://lnkd.in/e993_6u7 #RareDisease #Pharma #Biotech #HealthcareInnovation #WhitePaper

Starting January 2025, the European Union’s Joint Clinical Assessment (JCA) is set to transform the market access landscape for oncology and advanced therapy medicinal products (ATMP). At Putnam, we’re ready to guide you through these changes with tailored strategies that ensure your success. With our strategic planning, market access roadmaps, and patient-centered outcomes expertise, your product will be positioned for success. Connect with us to learn more about how our JCA offerings can help you thrive in this evolving landscape: https://lnkd.in/eS55xEbc #JCA #MarketAccess #Oncology #RegulatoryStrategy

Putnam Medical Affairs Practice Lead and Partner, Lori Klein, PharmD is participating in tomorrow's Medical Affairs Professional Society (MAPS) Insights Focus Area Working Group for their bimonthly discussion. This one will be focused on analyzing #insights. Join in the conversation!

Ready to take your asset prioritization to the next level? By leveraging advanced analytics and real-time data, AssetNav, part of the InizioNavigator suite, helps prioritize pipeline assets; supporting commercialization teams to make decisions on how to prioritize their resources and power strategic recommendations. Learn more about how our consultants can use this tool to help your organization: https://lnkd.in/eWjNZNmh #Pharma #AssetPrioritization #Data #AssetNav

ClarityNav allows our consultants to help you transform data into actionable insights. Simplify complex decision-making and drive impactful results with real-time analytics. Ready to navigate your data like never before? Learn more about the tool here: https://lnkd.in/eGbkXecb #AI #GenAI #Data #Insights #Healthcare #MedicalAffairs #ClarityNav

Ready to take your asset prioritization to the next level? At Putnam, we leverage advanced analytics and real-time data with AssetNav, part of the InizioNavigator suite, to help you to quickly identify and prioritize assets, powering smarter decision-making. Learn more about the AssetNav tool and how we use it here: https://lnkd.in/eaSVERAe #AssetPrioritization #Healthcare #Analytics #DataDriven #AssetNav #InizioNavigator

NOW accepting applications for our 2025 Life Sciences Consultant (LSC) positions! Are you interested in a unique role to allow you to gain insight and influence strategies for top biopharma clients? Have you demonstrated excellence and leadership in your educational experiences? Learn more about a career with Putnam and apply today: https://lnkd.in/eZzENcNm #Careers #OpenRoles #JobOpening #ApplyNow #NowHiring #LifeSciencesConsulting

In the fast-paced medical landscape, generative AI has become an essential ally, enabling Medical Affairs leaders to swiftly and accurately interpret vast amounts of data. For Putnam, we are at the forefront of this transformation with our cutting-edge proprietary AI tool, ClarityNav. In our latest blog by Lori Klein, PharmD, Partner, Medical and Scientific Affairs Practice Lead, discover how ClarityNav is enabling our consultants to redefine the way medical insights are gathered, analyzed, and applied. Read the piece here: https://lnkd.in/e3Qu69Eh #MedicalAffairs #GenerativeAI #MedicalInsights #ClarityNav #HealthcareInnovation